183 filings
Page 5 of 10
8-K
ov2iruvae9ojcdvyqq
8 Aug 11
Regulation FD Disclosure
12:00am
8-K
z0il8h 9o69
12 Jul 11
Other Events
12:00am
8-K
tb5t92ddtcd7
27 Jun 11
Other Events
12:00am
8-K
t5ipwq cr
13 Jun 11
Unigene Continues Solid Execution of Focused Turnaround Strategy and Monetizes Non-Core Asset with the Termination of China Joint Venture
12:00am
8-K
54a7h 95jcl63mteqv
10 Jun 11
Departure of Directors or Certain Officers
12:00am
8-K
ccp8 uyj09
6 Jun 11
Submission of Matters to a Vote of Security Holders
12:00am
8-K
xdsb3dqf1ausi dn
26 May 11
Other Events
12:00am
8-K
kub6o4onq
9 May 11
Unigene Reports First Quarter 2011 Financial Results
12:00am
8-K
pmt 6d3u0
27 Apr 11
Unigene Completes Patient Enrollment of Oral PTH Phase 2 Study for the Treatment of Osteoporosis in Postmenopausal Women
12:00am
8-K
v9fg0jstj53zf
13 Apr 11
Unigene Increases Support for Tarsa in Preparation for Oral Calcitonin NDA Submission
12:00am
8-K
d8gogtz8r4vvlk
24 Mar 11
Unigene’s Oral Peptide Drug Delivery Technology Validated with Positive Top-Line Phase 3 Results from Tarsa’s ORACAL Trial of Oral Calcitonin
12:00am
8-K
t7qphlfy0g5kv96 ki
15 Mar 11
Regulation FD Disclosure
12:00am
8-K
t3kgji32w2j
10 Mar 11
Unigene Reports Fourth Quarter and Full Year 2010 Financial Results
12:00am
8-K
fk9ek7oj
24 Feb 11
Unigene Accelerates the Development of its Lead Proprietary Anorexigenic Peptide UGP281 for Obesity
12:00am
8-K
hwezi5mu7bd5428wbu
14 Feb 11
Regulation FD Disclosure
12:00am
8-K
q81z1406i79bd
8 Feb 11
Departure of Directors or Certain Officers
12:00am
8-K
xwk9h
4 Feb 11
Entry into a Material Definitive Agreement
12:00am
8-K
64mk0
10 Jan 11
Unigene Provides 2011 Business Outlook
12:00am
8-K
yb9xbg7npg
13 Dec 10
Unigene to Advance Phase 2 Development of Oral PTH Program by Entering into an Amended and Restated Exclusive Worldwide License Agreement with GSK
12:00am
8-K
qv5zf
13 Dec 10
Unigene to Advance Phase 2 Development of Oral PTH Program by Entering into an Amended and Restated Exclusive Worldwide License Agreement with GSK
12:00am